Diabetes

Semaglutide (Ozempic; Novo Nordisk) approved as a once-weekly subcutaneous injection for the treatment of adults with type 2 diabetes.

Omnipod 5 allows patients with diabetes to receive 72 hours of continuous, automated insulin administration.

Factors such as economic stability and education access can be categorized into social determinants of health.

Pharmacy Times spoke to Susan Cornell, BS, PharmD, CDCES, FAPhA, FADCES, about her session she presented at the APhA 2022 Annual Meeting and Exposition, titled "Know the Facts: Annual Diabetes Update."

Andrew Bzowyckyi, PharmD, BCPS, CDCES, associate professor at Pacific University Oregon and clinic pharmacist at Legacy Medical Group discusses the differences in GLP-1 receptor agonists and insulin for the management of diabetes.

Exenatide (Bydureon) is a GLP-1 receptor agonist indicated to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.

Insurers, accountable care organizations, and manufacturers increasingly look for demonstrable clinical outcomes as proof for reimbursement or access to limited distribution networks.

Exenatide (Byetta) is a GLP-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Basaglar is indicated to improve glycemic control in adults and children with type 1 diabetes and adults with type 2 diabetes.

Important evidence about the health effects of e-cigarettes can help shape public health best practices in the United States, the findings of an analysis suggest.

Empagliflozin and linagliptin (Glyxambi) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Canagliflozin (Invokana) is indicated to improve glycemic control in adults with type 2 diabetes mellitus.

Alec Smith Insulin Affordability Act provides citizens with a long-term solution to diabetes expenditures.

Toujeo is used to improve glycemic control in adults with diabetes mellitus.

Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Tresiba is indicated to improve glycemic control in patients with diabetes.

Many faculty members are adept at training and teaching pharmacists and pharmacy technicians how to perform physical exams and tests.

Investigators find that a small protein cell glucagon-like peptide-1 (GLP-1) couples the body’s control of blood sugar and BP.

Pharmacists are essential team members for the education of patients with diabetes, especially around injection technique for patients using injectable medications, such as insulin.

Omnipod 5 is the first tubeless automated insulin delivery system that integrates with the Dexcom G6 Continuous Glucose Monitoring System and a compatible smartphone.

For patients with type 1 and type 2 diabetes, decisions around the selection of glucose meters can be difficult as there are several brands and types of meters available.

These results suggest that maternal diet during pregnancy can significantly affect obesity risk in children.

Although fewer than 1 in 5 adults with type 2 diabetes are meeting targets to reduce heart disease risk, available therapies can help when combined with new approaches that barriers to care.

The FGF1 hormone regulates blood glucose by inhibiting fat breakdown, although it works differently than insulin.

Point-of-care testing can vary in complexity, but is always performed at or near a patient and at the site where care or treatment is provided.

In patients with gestational diabetes, there is a higher risk of developing type 2 diabetes.

These lumps can relate to the overproduction of hormones, including the stress steroid hormone cortisol, which can lead to T2D and high blood pressure.

This is an update to the 2011 AAN guideline on the treatment of painful diabetic neuropathy, according to a press release.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), addresses her hopes for the future of SHC’s diabetes DRIVE program and its adoption within health systems.